Attolight
Founded Year
2008Stage
Series E | AliveTotal Raised
$6.12MLast Raised
$2.79M | 6 yrs agoAbout Attolight
Attolight builds microscopes to detect defects in semiconductor materials during the production process. Its proprietary technology is being employed for research purposes in such areas as light-emitting diode (LED), photovoltaic (solar) cells, and semiconductors. The company was founded in 2008 and is based in Lausanne, Switzerland.
Loading...
Loading...
Attolight Patents
Attolight has filed 6 patents.
The 3 most popular patent topics include:
- electron beam
- electron microscopy
- microscopes
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/19/2021 | 10/24/2023 | Electron beam, Spectroscopy, Electron microscopy, Microscopes, Accelerator physics | Grant |
Application Date | 7/19/2021 |
|---|---|
Grant Date | 10/24/2023 |
Title | |
Related Topics | Electron beam, Spectroscopy, Electron microscopy, Microscopes, Accelerator physics |
Status | Grant |
Latest Attolight News
Dec 22, 2022
Angstrom Scientific to distribute Attolight q-CL equipment Thursday 22nd December 2022 Company to distribute tools for inline defect inspection and high-end material research in North America Attolight AG announces the appointment of Angstrom Scientific Inc., as the North American (USA, Canada) distributor of its quantitative Cathodoluminescence (q-CL) equipment range. It features its automated solution for semiconductor inline defect inspection (Säntis 300) and its high-end material research tools in industrial R&D and academia (Allalin, Mönch). q-CL is a quantitative and non-destructive characterisation method that produces spectroscopic data at the nanoscale and provides a deeper understanding of the structure of materials. To better reach potential users of this technology, Attolight AG has entered into a distribution agreement with Angstrom Scientific Inc., a leading source for microscopy and spectroscopy products. Samuel Sonderegger, CEO of Attolight AG, was excited at the possibilities this new partnership would provide, “Angstrom Scientific is very well known in the field of electron microscopy and nano-science. Their relationships and history with researchers and institutions in this market will provide new opportunities for q-CL products to reach the people who will benefit most from their adoptions in the lab.” Bob Sommerville, CEO of Angstrom Scientific Inc., commented, “We are delighted to have the opportunity to work with the Attolight team, and to have the Mönch, Allalin and Säntis 300 spectroscopic CL products in the Angstrom portfolio. As we have gotten to know the management team we have the utmost confidence that we can continue to advance the Attolight presence in the North American market. The requirement to have high resolution defect inspection is only going to continue to grow and Attolight are in an excellent position to address this growing market”. CS International to return to Brussels – bigger and better than ever! The leading global compound semiconductor conference and exhibition will once again bring together key players from across the value chain for two-days of strategic technical sessions, dynamic talks and unrivalled networking opportunities. Join us face-to-face on 18-19 April 2023
Attolight Frequently Asked Questions (FAQ)
When was Attolight founded?
Attolight was founded in 2008.
Where is Attolight's headquarters?
Attolight's headquarters is located at EPFL Innovation Park, Lausanne.
What is Attolight's latest funding round?
Attolight's latest funding round is Series E.
How much did Attolight raise?
Attolight raised a total of $6.12M.
Who are the investors of Attolight?
Investors of Attolight include Verve Ventures, Zurcher Kantonalbank, Venture Kick and Swiss Federal Institute of Technology Lausanne.
Who are Attolight's competitors?
Competitors of Attolight include NanoPhotonics and 4 more.
Loading...
Compare Attolight to Competitors
Forth Photonics is a medical device company that designs, develops, manufactures and markets imaging systems for the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions. Forth Photonics aims to help medical practitioners to improve patient care by incorporating advanced biophotonics and optical molecular imaging technologies to assist in early detection, diagnosis and monitoring.
Real Imaging develops imaging solutions for breast cancer detection which is both accurate and patient-friendly. Its proprietary technology increases correct detection rates and decreases the number of false diagnoses for women of all ages around the globe. The company was founded in 2006 and is based in Lod, Israel.
Micrima develops a system to improve the detection of breast cancer. The imaging system captures three-dimensional (3D) images through the use of harmless radio waves. The safe, low-cost system enables women of all ages to be screened for breast cancer in GP surgeries, or alternative high street locations, with results that are now comparable with traditional X-ray mammograms. It was founded in 2006 and is based in Bristol, United Kingdom.
Orison Corporation was founded to design, manufacture and market a ultrasound technology platform for early breast cancer detection and diagnosis. Orison's technology aims to utilize Full Field Digital Ultrasound (FDDU) as an enabler that aims to allow the radiologist, for a time, to view breast tissue in a three dimensional environment. The outcome is earlier detection of breast cancer prior to metastasis, resulting in greater five-year survival rates and decreased treatment costs.
Microwave Imaging Systems Technology was founded in 1995 by Dr. Keith Paulsen and Dr. Paul Meaney of the Thayer School of Engineering and has developed a microwave-based, breast imaging system which aims to provide high-contrast images for breast cancer diagnostics. Per the company, the NIH has invested more than $6 million to develop and demonstrate the MIST system for tumor imaging. The company reports that testing on more than 150 patients has shown excellent detection of breast tumors.
a privately held, early stage medical device company focused on the development of imaging technology for biomedical use. The company is currently in stealth-mode and not disclosing the finer details of its technology until it secures necessary intellectual property rights. Spectral Image will initiate a pilot study of its technology at a premier medical facilities in 2008.
Loading...